Rizatriptan

Introduction Overview

Generic Name

rizatriptan

Brand Name

Maxalt, Maxalt-MLT

Dosage Form

oral tablet (5 mg, 10 mg), oral disintegrating tablet (5 mg, 10 mg)

Drug Class

Antimigraine agents

Pharmacokinetics

Absorption: Rizatriptan is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 1.5 hours post-dose. The orally disintegrating tablet formulation allows for rapid dissolution in the mouth, facilitating absorption even when patients experience nausea or vomiting associated with migraine attacks. Food intake does not significantly affect the bioavailability of rizatriptan, making dosing flexible with regard to meals. Clinical studies have demonstrated consistent pharmacokinetics across the tablet and orally disintegrating formulations, supporting their interchangeable use in practice. Factors such as gastric emptying time during migraine attacks can influence absorption rates but generally do not compromise efficacy.

Distribution: Rizatriptan exhibits a moderate volume of distribution, approximately 140 liters, indicating extensive tissue distribution. It is approximately 14% bound to plasma proteins, which facilitates widespread penetration across the blood-brain barrier to act on central nervous system targets implicated in migraine pathophysiology. Studies have shown that rizatriptan achieves therapeutic concentrations in the cerebral vasculature and trigeminal nerve terminals. The drug's distribution is not significantly altered by age, sex, or mild renal impairment, though severe hepatic impairment may affect distribution dynamics.

Metabolism: Rizatriptan undergoes primary hepatic metabolism predominantly by monoamine oxidase type A (MAO-A) to an inactive metabolite, 3-hydroxy-rizatriptan. This enzymatic pathway accounts for the majority of its biotransformation, while minor oxidative pathways contribute minimally. The activity of MAO-A is a critical determinant of the drug's elimination half-life and systemic exposure. Concomitant use of MAO inhibitors is contraindicated due to risk of elevated rizatriptan plasma levels and subsequent toxicity. Cytochrome P450 enzymes play a negligible role in rizatriptan metabolism, reducing the likelihood of interactions mediated through these pathways.

Elimination: The elimination half-life of rizatriptan is approximately 2 to 3 hours, with renal excretion accounting for about 70% of the administered dose, largely as metabolites; less than 10% is excreted unchanged in urine. Renal impairment can lead to modest increases in plasma rizatriptan levels, but dosage adjustment is generally not necessary in mild to moderate renal dysfunction. The rapid clearance facilitates repeat dosing within a 24-hour period if required, but maximum daily doses must be observed to avoid toxicity. Clinical monitoring is advised in cases of severe hepatic or renal impairment where elimination kinetics may be altered.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 5 mg, 10 mg
- Oral disintegrating tablet (Maxalt-MLT): 5 mg, 10 mg

Dosages for Adults and Adolescents:
- Adults with migraine: Initial dose is 5 mg or 10 mg orally once at onset of migraine headache.
- If symptoms persist or recur, a second dose may be administered at least 2 hours after the first dose.
- Maximum dose: 30 mg in a 24-hour period (e.g., three 10 mg tablets).
- For adolescents aged 6 years and older:
- Weighing less than 40 kg: initial dose 5 mg orally once.
- Weighing 40 kg or more: initial dose 10 mg orally once.
- Only one dose allowed in any 24-hour period in pediatric patients; safety and efficacy of multiple doses within 24 hours not established.

Specific Patient Populations:
- Rizatriptan is not approved for use in children under 6 years of age.
- Dosage adjustments are not typically required for mild to moderate renal impairment.
- Use with caution in patients with hepatic impairment; severe liver disease is a contraindication.
- Not recommended for basilar or hemiplegic migraine due to increased stroke risk.
- Oral disintegrating tablets contain phenylalanine and should be avoided in patients with phenylketonuria (PKU).
- Patients with cardiovascular risk factors (e.g., hypertension, coronary artery disease) require careful assessment before dosing.

Clinical Guidelines:
- Administer at the onset of migraine symptoms, not for prevention.
- Do not exceed recommended dosing frequency to minimize adverse effects.
- Monitor blood pressure regularly during therapy due to risk of hypertension elevation.

Mechanism Of Action

Rizatriptan is a selective serotonin (5-HT) receptor agonist, primarily targeting the 5-HT1B and 5-HT1D receptor subtypes. These receptors are localized on cranial blood vessels and nerve terminals in the trigeminovascular system, which plays a pivotal role in the pathogenesis of migraine headaches. Upon activation of 5-HT1B receptors on vascular smooth muscle, rizatriptan induces vasoconstriction of dilated intracranial blood vessels, thereby counteracting the vasodilation thought to contribute to migraine pain.

At the neuronal level, rizatriptan's agonist activity on 5-HT1D receptors located on trigeminal nerve endings inhibits the release of pro-inflammatory neuropeptides, such as calcitonin gene-related peptide (CGRP), substance P, and neurokinin A. This results in reduced neurogenic inflammation and modulation of pain transmission pathways involved in migraine attacks. The combined vascular and neuronal effects contribute to the rapid abortive action of rizatriptan in migraine treatment.

Biochemically, rizatriptan binds with high affinity and specificity to its target receptors, triggering downstream intracellular signaling cascades involving inhibition of adenylate cyclase and decreased cyclic AMP levels, leading to reduced release of neurotransmitters and neuropeptides. These molecular interactions explain the drug’s efficacy in alleviating migraine symptoms such as headache pain, nausea, and sensitivity to light and sound.

Clinical studies have demonstrated that rizatriptan provides significant pain relief within 30 to 60 minutes post-dose, correlating with peak plasma concentrations and receptor activation. Compared to other triptans, rizatriptan exhibits a favorable onset of action and tolerability profile. Research comparing rizatriptan with agents like sumatriptan indicates comparable efficacy but with a lower incidence of certain adverse vascular effects. Ongoing investigations explore rizatriptan’s modulation of central pain pathways, further elucidating its role in migraine therapy.

Pharmacological Actions

Selective agonist of serotonin 5-HT1B and 5-HT1D receptors.
Induces cranial vasoconstriction reversing migraine-associated vasodilation.
Inhibits release of pro-inflammatory neuropeptides from trigeminal nerve endings.
Modulates trigeminovascular pain pathways to alleviate migraine symptoms.
Exerts rapid onset of action, typically within 30 to 60 minutes post-administration.
Reduces migraine-associated symptoms including nausea, photophobia, and phonophobia.
Minimal interaction with cytochrome P450 enzymes, limiting metabolic drug interactions.
Demonstrates efficacy in acute migraine treatment but does not prevent attacks.
Low plasma protein binding facilitating efficient tissue distribution.
Rapid hepatic metabolism primarily by monoamine oxidase type A (MAO-A).
Therapeutic effects associated with inhibition of neurogenic inflammation.
Improves patient quality of life by reducing severity and duration of migraine episodes.

Therapeutic Or Clinical Uses

Acute treatment of migraine headaches with or without aura in adults.
Treatment of migraine in pediatric patients aged 6 years and older.
Alleviation of moderate to severe migraine pain.
Reduction of migraine-associated symptoms such as nausea and sensory sensitivities.
Useful in patients who require rapid relief of migraine symptoms at onset.
Not indicated for prophylactic or preventive migraine therapy.
Alternative migraine treatment option for patients intolerant to other triptans.
Management of migraine attacks confirmed by physician diagnosis.
Symptomatic treatment option for patients contraindicated for ergot derivatives.
Treatment approach integrated into comprehensive migraine management plans.
Off-label use cautiously considered by specialists for atypical migraine presentations.

Side Or Adverse Effects

Dizziness and drowsiness commonly reported during therapy.
Fatigue or feeling tired following administration.
Chest discomfort or pressure sensation, occasionally reported.
Rare occurrences of severe hypersensitivity reactions including hives and facial swelling.
Potential for serious cardiovascular events in patients with underlying heart disease.
Possible elevation of blood pressure, requiring monitoring.
Signs of serotonin syndrome in rare cases with concomitant serotonergic agents.
Nausea and gastrointestinal upset occasionally reported.
Transient sensations of warmth or flushing.
Rare neurological symptoms such as numbness or muscle stiffness.
Potential for rebound headaches if overused beyond recommended frequency.
Very rare reports of ischemic events including stroke or myocardial infarction.
Allergic reactions including rash or swelling requiring immediate medical attention.
Central nervous system effects including tremor or agitation in uncommon cases.

Precautions

Evaluate cardiovascular status prior to initiating rizatriptan due to vasoconstrictive properties.
Avoid use in patients with uncontrolled hypertension or significant heart disease.
Not recommended for treatment of basilar or hemiplegic migraines owing to stroke risk.
Caution advised in patients with liver impairment; severe hepatic disease contraindicates use.
Monitor blood pressure periodically during treatment due to potential hypertensive effects.
Use cautiously in patients with risk factors for coronary artery disease including age, smoking, diabetes, and hyperlipidemia.
Avoid concomitant use with MAO inhibitors within 14 days due to risk of toxicity.
Patients should inform providers about all medications to assess serotonin syndrome risk.
Orally disintegrating tablets contain phenylalanine; avoid in patients with phenylketonuria.
Not approved for children under 6 years of age; pediatric dosing requires clinical confirmation.
Patients should avoid driving or hazardous activities until drug effects are known.
Monitor for signs of hypersensitivity; discontinue if allergic reactions occur.
Avoid coadministration with other triptans or ergot alkaloids within 24 hours.
Use minimal effective dose to reduce risk of medication overuse headaches.

Warnings

Do not use if you have a history of heart attack, stroke, or uncontrolled hypertension.
Avoid rizatriptan within 24 hours before or after taking other migraine medications, including other triptans and ergot derivatives.
Concurrent use with monoamine oxidase inhibitors (MAOIs) within past 14 days is contraindicated due to risk of severe adverse effects.
Risk of serious cardiac events necessitates cardiovascular evaluation prior to treatment.
May cause sudden and severe gastrointestinal pain and bloody diarrhea indicative of ischemic colitis.
Possible occurrence of cold sensations or numbness in extremities representing vasospasm.
Be alert for symptoms of serotonin syndrome such as agitation, hallucinations, hyperthermia, and autonomic instability.
Discontinue use and seek emergency care if signs of stroke, myocardial infarction, or severe allergic reactions manifest.
Long-term safety for treating more than 4 migraine attacks per month has not been established.
Potential for increased blood pressure requiring regular monitoring during therapy.
Rizatriptan should not be used in migraine variants associated with high cerebrovascular risk.
Patients should be informed of risks related to medication overuse headaches with excessive use.
The safety and efficacy of multiple doses within 24 hours in pediatric patients remain unproven.
Use is contraindicated in patients with severe hepatic impairment.

Contraindication

Known hypersensitivity to rizatriptan or any formulation components.
Uncontrolled hypertension or severe cardiovascular disease, including coronary artery disease and angina.
History of myocardial infarction, stroke, or transient ischemic attacks (TIAs).
Presence of basilar or hemiplegic migraine due to increased stroke risk.
Use of monoamine oxidase inhibitors within the preceding 14 days.
Concurrent or recent use (within 24 hours) of other triptans or ergotamine-containing medications.
Severe hepatic impairment prohibiting safe metabolism and clearance.
Active peripheral vascular disease or ischemic bowel disease.
Phenylketonuria patients contraindicated for orally disintegrating tablets containing phenylalanine.
Hypersensitivity reactions to triptan class drugs constitute a contraindication.

Drug Interactions

Monoamine oxidase inhibitors significantly increase rizatriptan plasma levels; concurrent use contraindicated.
Other triptans or ergot alkaloids increase risk of additive vasoconstriction and hypertensive episodes; avoid use within 24 hours.
Propranolol increases rizatriptan plasma concentrations, potentially enhancing adverse effects; dose adjustment may be needed.
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) increase risk of serotonin syndrome when combined with rizatriptan.
Concomitant use with other serotonergic agents (e.g., antidepressants, opioids, herbal supplements like St. John’s Wort) requires caution.
Stimulant medications may exacerbate cardiovascular side effects when used with rizatriptan.
No significant interaction with cytochrome P450 substrates observed, given lack of CYP involvement in metabolism.
Potential pharmacodynamic interaction with antihypertensive drugs due to rizatriptan-induced vasoconstriction.
Co-administration with cimetidine does not significantly affect rizatriptan pharmacokinetics.
Ergot derivatives increase risk of coronary artery vasospasm; avoid concomitant use.
Inhibitors or inducers of MAO-A enzyme could alter rizatriptan metabolism affecting efficacy and safety.
Interactions with herbal products and over-the-counter medications should be reviewed to prevent adverse outcomes.
Medications affecting cardiac conduction may have additive effects with rizatriptan-induced cardiovascular changes.
Close monitoring is suggested when initiating or discontinuing interacting medications.

Preparations Of The Drug

Maxalt oral tablets available in 5 mg and 10 mg dosages.
Maxalt-MLT orally disintegrating tablets available in 5 mg and 10 mg formulations, facilitating administration without water.
RizaFilm, another orally disintegrating preparation, designed for ease of use during migraine attacks.
Tablets and orally disintegrating tablets supplied in blister packs to maintain stability.
Storage recommended at room temperature, protected from moisture and heat.
Formulations do not contain caffeine, making them suitable for patients avoiding stimulants.
Inactive ingredients in orally disintegrating tablets include phenylalanine, relevant for PKU patients.
Packaging includes clear dosing instructions to ensure patient compliance and safety.
Special packaging designed to preserve integrity of disintegrating formulations for rapid onset.
Labeling includes warnings on cardiovascular risks and serotonin syndrome potential.
Prescriptions typically supplied in quantities covering the acute treatment of multiple migraine episodes.
Oral routes are preferred due to rapid absorption and ease of administration during migraine attacks.